...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endocrine journal >Effect of High Dose Methylprednisolone Pulse Therapy Followed by Oral Prednisolone Administration on the Production of Anti-TSH Receptor Antibodies and Clinical Outcome in Graves' Disease
【24h】

Effect of High Dose Methylprednisolone Pulse Therapy Followed by Oral Prednisolone Administration on the Production of Anti-TSH Receptor Antibodies and Clinical Outcome in Graves' Disease

机译：口服强的松龙后大剂量甲基强的松龙脉冲治疗对Graves病抗TSH受体抗体产生和临床结果的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

References(33) Cited-By(10) Little is known about the immunosuppressive effect of glucocorticoids on TSH receptor antibodies. We observed the long-term prognosis and serum TSH binding inhibitor immunoglobulin (TBII) levels in patients with Graves' ophthalmopathy who had received intravenous methylprednisolone pulse therapy (pulse therapy) followed by oral prednisolone administration in order to ascertain how long the immunosuppressive effect of glucocorticoids continued. This is the first report on the effect of pulse therapy on Graves' disease outcome. We observed 67 patients who were treated by antithyroid drugs (ATD) alone for 2 years after pulse therapy. TBII was evaluated before and 3, 6, 12, 18, and 24 months after pulse therapy. The mean TBII decreased significantly 3 months after pulse therapy (p<0.001), and was maintained until 24 months. There were 24 patients whose TBII was positive (>15%) at 24 months, in whom the mean TBII decreased significantly 3 to 6 months after pulse therapy (p<0.001), but increased again at 12 to 24 months (p<0.05). Thus, the immunosuppressive effect of glucocorticoids may be lost at 12 months after pulse therapy in these patients. The remission rate in the pulse therapy group was 40.98%, and that of the control patient group was 48.57%. There was no significant difference between the two. These results suggest that the immunosuppressive effect of pulse therapy was temporary, and that pulse therapy did not increase remission rate of Graves' disease.
机译：参考文献（33）Cited-By（10）对糖皮质激素对TSH受体抗体的免疫抑制作用知之甚少。我们观察了Graves眼病患者的长期预后和血清TSH结合抑制剂免疫球蛋白（TBII）的水平，他们接受了静脉甲基强的松龙脉冲疗法（脉冲疗法），然后口服泼尼松龙口服给药，以确定糖皮质激素的免疫抑制作用持续了多长时间继续。这是关于脉冲疗法对格雷夫斯病结局影响的第一份报告。我们观察到67例在脉冲治疗后仅接受抗甲状腺药物（ATD）治疗2年的患者。在脉冲治疗之前和之后3、6、12、18和24个月评估TBII。脉冲治疗后3个月，平均TBII显着下降（p <0.001），并一直维持到24个月。在24个月时，有24例TBII阳性（> 15％）的患者，其中平均TBII在脉冲治疗后3至6个月显着下降（p <0.001），但在12到24个月时再次升高（p <0.05） 。因此，这些患者在接受脉冲治疗后12个月，糖皮质激素的免疫抑制作用可能会丧失。脉冲治疗组的缓解率是40.98％，对照组的缓解率是48.57％。两者之间没有显着差异。这些结果表明，脉冲疗法的免疫抑制作用是暂时的，并且脉冲疗法并未增加Graves病的缓解率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号